

UnitedHealthcare Pharmacy - Nevada  
Clinical Pharmacy Programs

|               |                                                                                     |
|---------------|-------------------------------------------------------------------------------------|
| Program       | Notification                                                                        |
| Medication    | Lidoderm® (transdermal lidocaine 5% patch)                                          |
| Date Approved | 2/2008                                                                              |
| Date Revised  | 12/2008, 11/2009, 11/2010, 11/2011, 4/2012, 4/2013, 8/2014, 7/2015, 6/2016, 11/2018 |

**1. Background:**

Lidoderm® (transdermal lidocaine) is FDA approved for post herpetic neuralgia and diabetic peripheral neuropathy. The National Comprehensive Cancer Network recognizes antiepileptic drugs, including gabapentin for treatment of chemotherapy induced peripheral neuropathy Lidoderm should be applied only to intact skin.

**2. Coverage Criteria:**

**A.** Lidocaine patch 5% (**Lidoderm**) will be approved based on **both** of the following criteria:

1. Diagnosis of neuropathic pain (eg, diabetic neuropathy, post-herpetic neuralgia, radiculopathy)

-AND-

2. **One** of the following:

- a. **Both** of the following:

- (1) Patient is < less than 65 years of age

-AND-

- (2) History of failure, contraindication, or intolerance to **two** of the following:

- (a) One (1) tricyclic antidepressant (eg, amitriptyline, nortriptyline or imipramine)
- (b) Gabapentin
- (c) Duloxetine

-OR-

- b. **Both** of the following:

(1) Patient is greater than or equal to 65 years of age

**-AND-**

(2) History of failure, contraindication, or intolerance **both** of the following:

(a) Gabapentin

(b) Duloxetine

**Authorization will be issued for 12 months**

### 3. Additional Clinical Programs:

### 4. References

1. Lidoderm (lidocaine patch 5%) Prescribing Information. Endo Pharmaceuticals Inc., January 2015 .
2. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-62.
3. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice Parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959-65.
4. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011; 76(20):1758-1765.
5. Tesfaye S, Boulton AJM, Dyck PJ et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33(10):2285-93.
6. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Pract. 2011;17(Suppl 2):1-53.
7. Stubblefield, MD, Burstein, HJ, Burton, AW NCCN Task Force Report: Management of Neuropathy in Cancer. JNCCN 2009;7[Suppl 5]:S1-S26

| Program               | Lidoderm® (transdermal lidocaine) Notification                                                                                  |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------|
| <b>Change Control</b> |                                                                                                                                 |
| Date                  | Change                                                                                                                          |
| 8/2014                | Annual review, no changes.                                                                                                      |
| 7/2015                | Added duloxetine to list of failure/contraindication/intolerance alternatives. Updated current and added additional references. |
| 6/2016                | Annual review, no changes                                                                                                       |

|         |                           |
|---------|---------------------------|
| 11/2018 | Annual review, no changes |
|---------|---------------------------|